Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(11):1544–1550. doi: 10.1054/bjoc.2001.1814

Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours

J J Casciari 1, N H Riordan 1,1, T L Schmidt 1, X L Meng 1, J A Jackson 2, H D Riordan 1
PMCID: PMC2363673  PMID: 11384106

Abstract

Vitamin C (ascorbate) is toxic to tumour cells, and has been suggested as an adjuvant cancer treatment. Our goal was to determine if ascorbate, in combination with other antioxidants, could kill cells in the SW620 hollow fibre in vitro solid tumour model at clinically achievable concentrations. Ascorbate anti-cancer efficacy, alone or in combination with lipoic acid, vitamin K 3, phenyl ascorbate, or doxorubicin, was assessed using annexin V staining and standard survival assays. 2-day treatments with 10 mM ascorbate increased the percentage of apoptotic cells in SW620 hollow fibre tumours. Lipoic acid synergistically enhanced ascorbate cytotoxicity, reducing the 2-day LC 50 in hollow fibre tumours from 34 mM to 4 mM. Lipoic acid, unlike ascorbate, was equally effective against proliferating and non-proliferating cells. Ascorbate levels in human blood plasma were measured during and after intravenous ascorbate infusions. Infusions of 60 g produced peak plasma concentrations exceeding 20 mM with an area under the curve (24 h) of 76 mM h. Thus, tumoricidal concentrations may be achievable in vivo. Ascorbate efficacy was enhanced in an additive fashion by phenyl ascorbate or vitamin K 3. The effect of ascorbate on doxorubicin efficacy was concentration dependent; low doses were protective while high doses increased cell killing. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: ascorbic acid (vitamin C); thioctic acid (lipoic acid); vitamin K; tumour cells, cultured; dose–responseelationship, drug

Full Text

The Full Text of this article is available as a PDF (106.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agus D. B., Vera J. C., Golde D. W. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999 Sep 15;59(18):4555–4558. [PubMed] [Google Scholar]
  2. Benade L., Howard T., Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole. Oncology. 1969;23(1):33–43. doi: 10.1159/000224465. [DOI] [PubMed] [Google Scholar]
  3. Bram S., Froussard P., Guichard M., Jasmin C., Augery Y., Sinoussi-Barre F., Wray W. Vitamin C preferential toxicity for malignant melanoma cells. Nature. 1980 Apr 17;284(5757):629–631. doi: 10.1038/284629a0. [DOI] [PubMed] [Google Scholar]
  4. Cameron E., Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974 Oct;9(4):285–315. doi: 10.1016/0009-2797(74)90019-2. [DOI] [PubMed] [Google Scholar]
  5. Cameron E., Pauling L., Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res. 1979 Mar;39(3):663–681. [PubMed] [Google Scholar]
  6. Cameron E., Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976 Oct;73(10):3685–3689. doi: 10.1073/pnas.73.10.3685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Casciari J. J., Hollingshead M. G., Alley M. C., Mayo J. G., Malspeis L., Miyauchi S., Grever M. R., Weinstein J. N. Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst. 1994 Dec 21;86(24):1846–1852. doi: 10.1093/jnci/86.24.1846. [DOI] [PubMed] [Google Scholar]
  8. Creagan E. T., Moertel C. G., O'Fallon J. R., Schutt A. J., O'Connell M. J., Rubin J., Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979 Sep 27;301(13):687–690. doi: 10.1056/NEJM197909273011303. [DOI] [PubMed] [Google Scholar]
  9. Fujita K., Shinpo K., Yamada K., Sato T., Niimi H., Shamoto M., Nagatsu T., Takeuchi T., Umezawa H. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res. 1982 Jan;42(1):309–316. [PubMed] [Google Scholar]
  10. Goldschmidt M. C. Reduced bactericidal activity in neutrophils from scorbutic animals and the effect of ascorbic acid on these target bacteria in vivo and in vitro. Am J Clin Nutr. 1991 Dec;54(6 Suppl):1214S–1220S. doi: 10.1093/ajcn/54.6.1214s. [DOI] [PubMed] [Google Scholar]
  11. Henson D. E., Block G., Levine M. Ascorbic acid: biologic functions and relation to cancer. J Natl Cancer Inst. 1991 Apr 17;83(8):547–550. doi: 10.1093/jnci/83.8.547. [DOI] [PubMed] [Google Scholar]
  12. Hornig D. Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann N Y Acad Sci. 1975 Sep 30;258:103–118. doi: 10.1111/j.1749-6632.1975.tb29271.x. [DOI] [PubMed] [Google Scholar]
  13. Jonas S. K., Riley P. A., Willson R. L. Hydrogen peroxide cytotoxicity. Low-temperature enhancement by ascorbate or reduced lipoate. Biochem J. 1989 Dec 15;264(3):651–655. doi: 10.1042/bj2640651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koch C. J., Biaglow J. E. Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells. J Cell Physiol. 1978 Mar;94(3):299–306. doi: 10.1002/jcp.1040940307. [DOI] [PubMed] [Google Scholar]
  15. Kurbacher C. M., Wagner U., Kolster B., Andreotti P. E., Krebs D., Bruckner H. W. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996 Jun 5;103(2):183–189. doi: 10.1016/0304-3835(96)04212-7. [DOI] [PubMed] [Google Scholar]
  16. Langemann H., Torhorst J., Kabiersch A., Krenger W., Honegger C. G. Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int J Cancer. 1989 Jun 15;43(6):1169–1173. doi: 10.1002/ijc.2910430634. [DOI] [PubMed] [Google Scholar]
  17. Leung P. Y., Miyashita K., Young M., Tsao C. S. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res. 1993 Mar-Apr;13(2):475–480. [PubMed] [Google Scholar]
  18. Moertel C. G., Fleming T. R., Creagan E. T., Rubin J., O'Connell M. J., Ames M. M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985 Jan 17;312(3):137–141. doi: 10.1056/NEJM198501173120301. [DOI] [PubMed] [Google Scholar]
  19. Murata A., Morishige F., Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl. 1982;23:103–113. [PubMed] [Google Scholar]
  20. Noto V., Taper H. S., Jiang Y. H., Janssens J., Bonte J., De Loecker W. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. Cancer. 1989 Mar 1;63(5):901–906. doi: 10.1002/1097-0142(19890301)63:5<901::aid-cncr2820630518>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  21. Okunieff P., Suit H. D. Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine fibrosarcomas. J Natl Cancer Inst. 1987 Aug;79(2):377–381. [PubMed] [Google Scholar]
  22. Ou P., Tritschler H. J., Wolff S. P. Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem Pharmacol. 1995 Jun 29;50(1):123–126. doi: 10.1016/0006-2952(95)00116-h. [DOI] [PubMed] [Google Scholar]
  23. Penn N. D., Purkins L., Kelleher J., Heatley R. V., Mascie-Taylor B. H., Belfield P. W. The effect of dietary supplementation with vitamins A, C and E on cell-mediated immune function in elderly long-stay patients: a randomized controlled trial. Age Ageing. 1991 May;20(3):169–174. doi: 10.1093/ageing/20.3.169. [DOI] [PubMed] [Google Scholar]
  24. Riordan N. H., Riordan H. D., Meng X., Li Y., Jackson J. A. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses. 1995 Mar;44(3):207–213. doi: 10.1016/0306-9877(95)90137-x. [DOI] [PubMed] [Google Scholar]
  25. Taper H. S., Keyeux A., Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res. 1996 Jan-Feb;16(1):499–503. [PubMed] [Google Scholar]
  26. Tsao C. S., Dunham W. B., Leung P. Y. In vivo antineoplastic activity of ascorbic acid for human mammary tumor. In Vivo. 1988 Mar-Apr;2(2):147–150. [PubMed] [Google Scholar]
  27. Varga J. M., Airoldi L. Inhibition of transplantable melanoma tumor development in mice by prophylactic administration of Ca-ascorbate. Life Sci. 1983 Apr 4;32(14):1559–1564. doi: 10.1016/0024-3205(83)90861-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES